Fovista®, a once-promising experimental drug for treatment of wet macular degeneration, has failed to show positive results in Phase 3 trials. This is surprising, since, on June 14, 2012, Ophthotech Corporation reported a 62% higher relative visual benefit when Fovista (1.5 mg) was used in combination with Lucentis in Phase 2b clinical trials. Based upon those […]
(Updated 11/8/17) A new non-invasive technology from LumiThera Inc. may help improve vision in people with dry age-related macular degeneration. Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best […]
The Cochrane Eyes and Vision US Satellite (CEV@US), located at The Johns Hopkins Bloomberg School of Public Health (JHBSPH) is conducting an important survey to identify research priorities for age-related macular degeneration (AMD). Their previous request for participants in the survey has yielded 35 responses so far, but at least 50 are needed. The survey will take […]